Awareness about causes of gastrointestinal tract [GIT] malignancies

To determine the knowledge of doctors, nurses, patients and public about the causes of gastrointestinal cancers and dissemination of this knowledge. Design: A cross-sectional analytical study. Place and Duration of Study: This study was carried out in the Department of Oncology, King Fahad Hospital, Al-Madinah Al-Munawara, Kingdom of Saudi Arabia and was completed in four months from February 2003 to June 2003. Subjects and About 200 doctors, nurses and patients suffering from GIT cancer and general public were selected. Each subject was asked to fill up a proforma designed to assess his knowledge about the risk factors for GIT malignancies. A majority of doctors and nurses had good knowledge about the causes of GIT malignancies. The knowledge of patients and general public was low. Out of all four groups, it was poorest in the patient's group. The difference in the knowledge of medicos and patients/public reflects that medicos should convey this knowledge to the patients in particular and general public in general, which is their responsibility besides medical treatment

Role of COX-2 specific inhibitors in oncogenesis

Cyclooxygenase-2 [COX-2] is over expressed in a variety of premalignant and malignant conditions. It may contribute to carcinogenesis by modulating xenobiotic metabolism, apoptosis, immune surveillance, and angiogenesis. Selective COX-2 inhibitors suppress the formation of tumors in experimental models. Selective COX-2 inhibitors also suppress the growth and metastases of established tumors and enhance the anticancer activity of both radiotherapy and chemotherapy in experimental animals. This review aims at discussing evidence that inhibition of COX-2 represents a promising strategy to treat, prevent or possibly prevent human malignancies. Importantly, selective COX-2 inhibitors do not inhibit platelet function and cause fewer gastrointestinal side effects [peptic ulcer disease] than traditional nonsteroidal anti-inflammatory drugs [NSAIDS]. More clinical trials are warranted to define the role of selective COX-2 inhibitors in the prevention and treatment of cancer along with their assessment of toxicity